FibroBiologics, Inc. 8-K

What Happened
FibroBiologics, Inc. announced a one-for-twenty (1:20) reverse stock split of its common stock. The company filed a Certificate of Amendment on March 25, 2026, which became effective at 12:01 a.m. Eastern Time on March 30, 2026. The trading symbol remains “FBLG” and the CUSIP for the common stock changed to 31573L204.

Key Details

• Reverse split ratio: 1-for-20 — every 20 shares were converted into 1 share.
• Effective date/time: Certificate effective March 30, 2026 at 12:01 a.m. ET; filed March 25, 2026.
• Fractional shares: No fractional shares will be issued; any fractional result will be rounded up to the nearest whole share.
• Other effects: Par value and authorized number of shares were unchanged; the number of shares available under the company’s equity incentive plan and the exercise price/number of shares underlying outstanding options and warrants were proportionately adjusted.
• Filing notes: The 8-K lists Item 3.03 (Material Modification to Rights of Security Holders) where applicable, but the primary disclosed action is the reverse stock split under Item 5.03.

Why It Matters
A reverse stock split reduces the number of outstanding shares and raises the per-share price without changing a shareholder’s proportional ownership (aside from rounding for fractional shares). For investors, this can affect share liquidity, trading price per share, and how the company meets listing standards or investor perception. The filing confirms option/warrant and equity plan adjustments will be made proportionately, so holders of those instruments should expect corresponding changes to strike prices and share counts.